Tisagenlecleucel for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukaemia in People Aged up to 25 Years: An Evidence Review Group Perspective of a NICE Single Technology…

Overview of attention for article published in PharmacoEconomics, April 2019

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 2 X users

facebook: 1 Facebook page

Citations

dimensions_citation: 24 Dimensions

Readers on

mendeley: 103 Mendeley

Summary X Facebook Dimensions citations

So far, Altmetric has seen 1 public wall post.

Healtheconbot, 13 Apr 2019

#HealthEconJA Tisagenlecleucel for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukaemia in People Aged…